Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Methotrexate Shows Promise for Hand Arthritis

Deborah Levenson  |  June 10, 2024

Methotrexate—an affordable, established drug for rheumatoid arthritis—may also be helpful for patients suffering from osteoarthritis (OA) of the hand, a recent study reports.1 Treatment of hand OA and inflammation with 20 mg of methotrexate for six months had a moderate, but potentially clinically meaningful, effect on reducing pain and stiffness in patients with symptomatic hand…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersResearch ReviewsResearch Rheum Tagged with:hand osteoarthritisMethotrexatesynovitis

Methylprednisolone & Methotrexate: Codes & Billing Updated

From the College  |  April 22, 2024

As of April 1, HCPCS codes for methylprednisolone have changed. The ACR is working with the CMS to determine how rheumatologists should bill Medicare corrrectly.

Filed under:Billing/CodingPractice ManagementPractice Support Tagged with:MethotrexateMethylprednisolone

Pegloticase Plus Methotrexate Effective for Uncontrolled Gout

Glen Rodman  |  August 8, 2023

The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:ACR Open RheumatologyGoutGout Resource CenterMethotrexatepegloticaseserum urate levels

Methotrexate Shortage: Why It’s Happening & Potential Solutions

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2023

In recent months, many rheumatologists and rheumatology professionals have noted issues related to obtaining supplies of injectable and oral methotrexate for their patients with rheumatoid arthritis (RA). A conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), methotrexate is available as both oral tablets and as a subcutaneous injection for the treatment of RA and other autoimmune diseases.1…

Filed under:Drug Updates Tagged with:Drug shortagedrug treatmentMethotrexatepatient careRheumatoid Arthritis (RA)

How Long Should Methotrexate Be Held Following Seasonal Vaccinations?

Arthritis & Rheumatology  |  February 1, 2023

Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.

Filed under:ConditionsResearch Rheum Tagged with:Arthritis & RheumatologyMethotrexateResearchvaccination

Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease

Michele B. Kaufman, PharmD, BCGP  |  December 12, 2022

Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.

Filed under:Drug Updates Tagged with:ACR Convergence 2022MethotrexateRheumatoid Arthritis (RA)toxicity

Prokopenko Oleg / shutterstock.com

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

Vanessa Caceres  |  January 10, 2022

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (metho­trexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch Rheum Tagged with:GoutGout Resource CenterMethotrexatepegloticase

Methotrexate

Maxed Out Methotrexate?

Staff  |  November 22, 2021

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

Vanessa Caceres  |  March 9, 2021

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – RAadalimumabjakinibupadacitinib

Pulmonary Adverse Events with Low-Dose Methotrexate

Arthritis & Rheumatology  |  November 24, 2020

In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.

Filed under:ConditionsDrug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyResearch

  • 1
  • 2
  • 3
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences